|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Juliusson G, Lazarevic V, Hörstedt AS,
Hagberg O and Höglund M; Swedish Acute Leukemia Registry Group:
Acute myeloid leukemia in the real world: Why population-based
registries are needed. Blood. 119:3890–3899. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li WY, Wang Y, Chen SN, Qiu HY, Fu ZZ, Wu
DP and Sun AN: Consolidation therapy with decitabine and
intermediate-dose cytarabine followed by HLA-mismatched peripheral
blood stem cells infusion for older patients with acute myeloid
leukemia in first remission. Leuk Lymphoma. 59:1652–1658. 2018.
View Article : Google Scholar
|
|
4
|
Thol F, Schlenk RF, Heuser M and Ganser A:
How I treat refractory and early relapsed acute myeloid leukemia.
Blood. 126:319–327. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sasine JP and Schiller GJ: Emerging
strategies for high-risk and relapsed/refractory acute myeloid
leukemia: Novel agents and approaches currently in clinical trials.
Blood Rev. 29:1–9. 2015. View Article : Google Scholar
|
|
6
|
Li G, Ren L, Li G, et al: The
effectiveness comparison between the CLAG regimens and MEA regimens
for the treatment of patients with relapsed or refractory acute
myeloid leukemia. J Mod Oncol. 26:264–268. 2018.In Chinese.
View Article : Google Scholar
|
|
7
|
Corces-Zimmerman MR, Hong WJ, Weissman IL,
Medeiros BC and Majeti R: Preleukemic mutations in human acute
myeloid leukemia affect epigenetic regulators and persist in
remission. Proc Natl Acad Sci USA. 111:2548–2553. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tan Y, Liu H and Chen S: Mutant DNA
methylation regulators endow hematopoietic stem cells with the
preleukemic stem cell property, a requisite of leukemia initiation
and relapse. Front Med. 9:412–420. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the World Health Organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bennett JM, Catovsky D, Daniel MT,
Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposals for the
classification of the acute leukemias. French-American-British
(FAB) co-operative group. Br J Haematol. 33:451–458. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
NCCN: Acute Myeloid Leukemia, NCCN
Clinical Practice Guidelines in Oncology. Accessed April 4,
2016.
|
|
12
|
Döhner H, Estey E, Grimwade D, Amadori S,
Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA,
et al: Diagnosis and management of AML in adults: 2017 ELN
recommendations from an international expert panel. Blood.
129:424–447. 2017. View Article : Google Scholar :
|
|
13
|
Cheson BD, Bennett JM, Kopecky KJ, Büchner
T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister
TA, et al: Revised recommendations of the International Working
Group for Diagnosis, Standardization of Response Criteria,
Treatment Outcomes, and Reporting Standards for Therapeutic Trials
in Acute Myeloid Leukemia. J Clin Oncol. 21:4642–4649. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Spencer DH, Russler-Germain DA, Ketkar S,
Helton NM, Lamprecht TL, Fulton RS, Fronick CC, O′Laughlin M, Heath
SE, Shinawi M, et al: CpG island hypermethylation mediated by
DNMT3A is a consequence of AML progression. Cell. 168:801–816.e13.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Deneberg S, Grövdal M, Karimi M, Jansson
M, Nahi H, Corbacioglu A, Gaidzik V, Döhner K, Paul C, Ekström TJ,
et al: Gene-specific and global methylation patterns predict
outcome in patients with acute myeloid leukemia. Leukemia.
24:932–941. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Döhner H, Weisdorf DJ and Bloomfield CD:
Acute myeloid leukemia. N Engl J Med. 373:1136–1152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Short NJ, Rytting ME and Cortes JE: Acute
myeloid leukaemia. Lancet. 392:593–606. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Welch JS, Petti AA, Miller CA, Fronick CC,
O′Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon
B, et al: TP53 and decitabine in acute myeloid leukemia and
myelodys-plastic syndromes. N Engl J Med. 375:2023–2036. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bai X, Xiao X, Li Y, Zhao M and Deng Qi:
Curative effect of CAG regimen compared with CAG combined with
decitabine regimen in elderly patients with acute myeloid leukemia.
Clin Focus. 33:240–243. 2018.In Chinese.
|
|
20
|
Metzeler KH, Walker A, Geyer S, Garzon R,
Klisovic RB, Bloomfield CD, Blum W and Marcucci G: DNMT3A mutations
and response to the hypomethylating agent decitabine in acute
myeloid leukemia. Leukemia. 26:1106–1107. 2012. View Article : Google Scholar
|
|
21
|
Kantarjian HM, Thomas XG, Dmoszynska A,
Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R,
Cermak J, et al: Multicenter, randomized, open-label, phase III
trial of decitabine versus patient choice, with physician advice,
of either supportive care or low-dose cytarabine for the treatment
of older patients with newly diagnosed acute myeloid leukemia. J
Clin Oncol. 30:2670–2677. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thomas XG, Arthur C, Delaunay J, Jones M,
Berrak K and Kantarjian HM: A post hoc sensitivity analysis of
survival probabilities in a multinational phase III trial of
decitabine in older patients with newly diagnosed acute myeloid
leukemia. Clin Lymphoma Myeloma Leuk. 14:68–72. 2014. View Article : Google Scholar
|
|
23
|
Nieto M, Demolis P, Béhanzin E, Moreau A,
Hudson I, Flores B, Stemplewski H, Salmonson T, Gisselbrecht C,
Bowen D and Pignatti F: The European medicines agency review of
decitabine (Dacogen) for the treatment of adult patients with acute
myeloid leukemia: Summary of the scientific assessment of the
committee for medicinal products for human use. Oncologist.
21:692–700. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Figueroa ME, Abdel-Wahab O, Lu C, Ward PS,
Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, et
al: Leukemic IDH1 and IDH2 mutations result in a hypermethylation
phenotype, disrupt TET2 function, and impair hematopoietic
differentiation. Cancer Cell. 18:553–567. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rothenberg-Thurley M, Amler S, Goerlich D,
Köhnke T, Konstandin NP, Schneider S, Sauerland MC, Herold T,
Hubmann M, Ksienzyk B, et al: Persistence of pre-leukemic clones
during first remission and risk of relapse in acute myeloid
leukemia. Leukemia. 32:1598–1608. 2018. View Article : Google Scholar : PubMed/NCBI
|
